Literature DB >> 1657238

Pharmacokinetics of azithromycin after single oral dosing of experimental animals.

D Davila1, L Kolacny-Babić, F Plavsić.   

Abstract

Azithromycin, a macrolide antibiotic with an enhanced antimicrobial spectrum, was found to have a longer half-life than erythromycin, with marked tissue penetration. The pharmacokinetics of azithromycin after oral administration were compared with those of erythromycin in rats (200 mg kg-1) and rabbits (80 mg kg-1). Concentrations of azithromycin in liver, lung, kidney, ileum, and brain were higher than serum concentrations. The slow decline in tissue concentrations was evident from the biphasic elimination profile. Thus, advantageous pharmacokinetic properties and the broader antimicrobial spectrum of azithromycin relative to erythromycin appear to further support its therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657238     DOI: 10.1002/bdd.2510120704

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  9 in total

1.  Rationale for a Neisseria gonorrhoeae Susceptible-only Interpretive Breakpoint for Azithromycin.

Authors:  Ellen N Kersh; Vanessa Allen; Eric Ransom; Matthew Schmerer; Sancta Cyr; Kim Workowski; Hillard Weinstock; Jean Patel; Mary Jane Ferraro
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

2.  Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo.

Authors:  J G den Hollander; J D Knudsen; J W Mouton; K Fuursted; N Frimodt-Møller; H A Verbrugh; F Espersen
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

3.  Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells.

Authors:  Julian Laux; Michael Forster; Laura Riexinger; Anna Schwamborn; Jamil Guezguez; Christina Pokoj; Mark Kudolo; Lena M Berger; Stefan Knapp; Dieter Schollmeyer; Jan Guse; Michael Burnet; Stefan A Laufer
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-14

4.  Pharmacokinetics of spiramycin in the rhesus monkey: transplacental passage and distribution in tissue in the fetus.

Authors:  E Schoondermark-Van de Ven; J Galama; W Camps; T Vree; F Russel; J Meuwissen; W Melchers
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  Azithromycin does not alter the effects of oral midazolam on human performance.

Authors:  M J Mattila; J Vanakoski; J J Idänpään-Heikkilä
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Maternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy.

Authors:  Matthew W Kemp; Yuichiro Miura; Matthew S Payne; Alan H Jobe; Suhas G Kallapur; Masatoshi Saito; Sarah J Stock; O Brad Spiller; Demelza J Ireland; Nobuo Yaegashi; Michael Clarke; Dorothee Hahne; Jennifer Rodger; Jeffrey A Keelan; John P Newnham
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

7.  Macrolide antibiotics like azithromycin increase lipopolysaccharide-induced IL-8 production by human gingival fibroblasts.

Authors:  A Kamemoto; T Ara; T Hattori; Y Fujinami; Y Imamura; Pao-Li Wang
Journal:  Eur J Med Res       Date:  2009-07-22       Impact factor: 2.175

8.  Repurposing azithromycin for neonatal neuroprotection.

Authors:  John D E Barks; Yiqing Liu; Lu Wang; Manjunath P Pai; Faye S Silverstein
Journal:  Pediatr Res       Date:  2019-05-17       Impact factor: 3.756

9.  Azithromycin Affords Neuroprotection in Rat Undergone Transient Focal Cerebral Ischemia.

Authors:  Diana Amantea; Francesco Petrelli; Rosaria Greco; Cristina Tassorelli; Maria Tiziana Corasaniti; Paolo Tonin; Giacinto Bagetta
Journal:  Front Neurosci       Date:  2019-11-26       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.